Clinical Trial

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-01-02 -> 2028-07-01 2026-07-24
minor Completion pushed: 2028-01-02 -> 2028-07-01 2026-07-24
Trial Details
NCT Number NCT07172919
Lead Sponsor Amgen
Conditions Advanced Solid Tumors
Enrollment 14 participants
Start Date 2026-01-02
Primary Completion 2028-07-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-23